BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Teva Posts 2021 Earnings and Puts Opioid Litigation in Rearview Mirror

  Teva Pharmaceuticals reported solid earnings for the full year of 2021, posting $15.9 billion in revenues alongside gains of $4.1 billion from the fourth quarter alone.

  February 10, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Novartis-Partnered COVID-19 Antiviral Seeks Emergency Use Authorization

  The EUA request is based on the Phase II study that showed treatment with ensovibep reduced the viral load from the SARS-CoV-2 virus within eight days of use compared to placebo.

  February 10, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Research Roundup: Vitamin D Deficiency and Severe COVID-19

  Recent research supports a link between vitamin D deficiency and severe COVID-19. Here’s a look.

  February 10, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  Alnylam’s Shares Slide Despite 83% Revenue Growth in 2021

  Shares of Alnylam Pharmaceuticals are sliding in morning trading despite the news that the company’s revenues grew by 83% in 2021 compared to the previous year.

  February 10, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Genetown

  Arkuda Reels in Another $64M to Disrupt Neurodegenerative Disease Treatment

  Arkuda seeks to disrupt the usual progression of neurodegenerative disease with medicines developed by applying cutting-edge knowledge from the domains of lysosomal and microglial biology.

  February 10, 2022

   · 

  2 min read

   · 

  Claudia Beezhold
• 

  Business

  BioSpace Movers & Shakers, Feb. 11

  Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

  February 10, 2022

   · 

  9 min read

   · 

  Alex Keown
• 

  Policy

  AACR Calls for More Funding for Basic Research and Telehealth Equity

  The speakers extolled the benefits of telehealth while noting the challenges posed by a lack of high-speed Internet in some parts of the country.

  February 10, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Merck’s Keytruda Helps Again: This Time in Triple-Negative Breast Cancer

  Merck has announced positive results from its Phase III KEYNOTE-522 study on the use of KEYTRUDA alongside chemotherapy in high-risk early-stage triple-negative breast cancer.

  February 10, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Oxford Professor: Tarnished AstraZeneca Vaccine Rep Probably “Killed Hundreds of Thousands”

  As AstraZeneca released its 2021 annual financial report, a BBC documentary suggested that the way scientists and politicians politicized its COVID-19 vaccine may have cost lives.

  February 10, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Biotech Stocks Take Hit as Wary Investors Look Elsewhere

  The London-based Financial Times reported that 83% of companies listed on stock exchanges over the past two years are now trading well below their initial public offering price.

  February 10, 2022

   · 

  3 min read

   · 

  Alex Keown